Dyne Therapeutics (DYN) Interest Expenses (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Interest Expenses data on file, last reported at $49.4 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 653.92% year-over-year to $49.4 million in Q1 2026; TTM through Mar 2026 was $49.4 million, a 653.92% increase from a year earlier, with the FY2025 full-year figure at $52.8 million, down 81.72% from the prior year.
• Interest Expenses for Q1 2026 stood at $49.4 million, up from $2.5 million in the prior quarter.
• Over the last five years, Interest Expenses for DYN reached as high as $178.0 million in Q2 2024 and fell as low as $94000.0 in Q2 2025.
• Historically, Interest Expenses has averaged $49.6 million across 5 years, with a median of $26.3 million in 2022.
• Across the five-year window, Interest Expenses jumped 55871.43% in 2022 and slumped 99.95% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $113.6 million in 2022, then gained by 28.3% to $145.8 million in 2023, then sank by 96.58% to $5.0 million in 2024, then sank by 48.89% to $2.5 million in 2025, then surged by 1839.59% to $49.4 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $49.4 million in Q1 2026, $2.5 million in Q4 2025, and $2.9 million in Q3 2025.